Meeting
2022 ASCO Annual Meeting
A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.
Authors
Won Seog Kim
Samsung Medical Center, Seoul, South Korea
Won Seog Kim , Dok Hyun Yoon , Yuqin Song , Haiyan Yang , Junning Cao , Dongmei Ji , Youngil Koh , Hongmei Jing , Hyeon Seok Eom , Jae-Yong Kwak , Won-Sik Lee , Jong Seok Lee , Ho-Jin Shin , Jie Jin , Mei Wang , Jingrun Li , Xubin Huang , Xueyuan Deng , Zhenfan Yang , Jun Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04105010
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7563)
DOI
10.1200/JCO.2022.40.16_suppl.7563
Abstract #
7563
Poster Bd #
216
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
First Author: Benjamin L. Schlechter
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess
Poster
2022 ASCO Annual Meeting
SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.
First Author: Yuqin Song
Poster
2018 ASCO Annual Meeting
The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).
First Author: Steven M. Horwitz